Risk factors for raltegravir resistance development in clinical practice

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2494-2500

  Malet, Isabelle ^a   Fourati, Slim ^a   Morand Joubert, Laurence ^a   Flandre, Philippe ^a   Wirden, Marc ^a   Haim Boukobza, Stéphanie ^a   Sayon, Sophie ^a   Pattery, Theresa ^b   Simon, Anne ^c   Katlama, Christine ^a   Girard, Pierre Marie ^a   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Virco BVBA   (Belgium)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Failure; HIV 1; Integrase; Raltegravir; Resistance mutations

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; DRUG TREATMENT FAILURE; FEMALE; GENETIC RISK; GENETIC SELECTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; TREATMENT DURATION; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PYRROLIDINONES; RISK FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84866595664     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks254     Document Type: Article

References (23)

1. Lennox JL, DeJesus E, Lazzarin A et al. Safety and efficacy of raltegravirbased versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
2. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-54.
3. Mbisa JL, Martin SA, Cane PA. Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist 2011; 4: 65-76.
4. Métifiot M, Marchand C, Maddali K et al. Resistance to integrase inhibitors. Viruses 2010; 2: 1347-66.
5. Okeke NL, Hicks C. Role of raltegravir in the management of HIV-1 infection. HIV AIDS (Auckl) 2011; 3: 81-92.
6. Cooper DA, Steigbigel RT, Gatell JM et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359: 355-65.
7. Geretti AM, Fearnhill E, Ceccherini-Silberstein F et al. Prevalence and patterns of raltegravir resistance in treated patients in Europe. In: Abstracts of the International HIV and Hepatitis Virus Drug Resistance Workshop, Dubrovnik, Croatia, 2010. Abstract A62.
8. Malet I, Delelis O, Soulie C et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63: 795-804.
9. Malet I, Delelis O, Valantin MA et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008; 52: 1351-8.
10. Kozal M, Lupo S, DeJesus E et al. The SPARTAN study: a pilot study to assess the safety and efficacy of an investigational NRTI- and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg BID plus raltegravir (RAL) 400 mg BID (ATV+RAL) in treatment-naive HIV-infected subjects. In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract THLBB204.
11. Eron JJ, Young B, Cooper DA et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396-407
12. Yeni P. Prise en charge médicale des personnes infectées par le VIH. 2010. http://www.sante.gouv.fr (19 June 2012, date last accessed).
13. Van Baelen K, Van Eygen V, Rondelez E et al. Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility. AIDS 2008; 22: 1877-80
14. Nagelkerke NJ. A note on a general definition of the coefficient of determination. Biometrika 1991; 78: 691-2.
15. Garrido C, Geretti AM, Zahonero N et al. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. J Antimicrob Chemother 2010; 65: 320-6.
16. Rowley M. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Prog Med Chem 2008; 46: 1-28.
17. Shimura K, Kodama E, Sakagami Y et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 2008; 82: 764-74.
18. Malet I, Fourati S, Charpentier C et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype. J Antimicrob Chemother 2011; 66: 2827-30.
19. Bar-Magen T, Sloan RD, Donahue DA et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84: 9210-6.
20. Kobayashi M, Nakahara K, Seki T et al. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res 2008; 80: 213-22.
21. Ceccherini-Silberstein F, Malet I, D'Arrigo R et al. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev 2009; 11: 17-29.
22. Malet I, Soulie C, Tchertanov L et al. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 2008; 80: 754-61.
23. Rhee SY, Liu TF, Kiuchi M et al. Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008; 5: 74.